While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results